Payment overview · 2025
General Payments
$224.59
11 reported records · 6 companies
Healthcare provider profile · identity verified
Alfonso E Martinez, M.D.
Allopathic & Osteopathic Physicians|General Practice · OCALA, FL · NPI 1013192798
Verified facts
What the public records show
CMS Open Payments records show Alfonso E Martinez, M.D. received $224.59 in general payments during 2025 across 11 reported records.
Bayer Healthcare Pharmaceuticals Inc. accounted for 44.6% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 9 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Mounjaro.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 140 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Trulicity by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NUEDEXTA as an associated drug or biological on 393 records involving 285 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Nuedexta by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 872 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $100.25 | 44.6% | 5 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $49.77 | 22.2% | 2 | 2025 |
| REVANCE THERAPEUTICS, INC. | Unresolved — no canonical attribution shown | $24.16 | 10.8% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $18.69 | 8.3% | 1 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $17.13 | 7.6% | 1 | 2025 |
| ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | Unresolved — no canonical attribution shown | $14.59 | 6.5% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $224.59 | 11 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $100.25 | 5 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $49.77 | 2 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $27.32 | 1 | 2025 |
Source payment records
|
|||||
| DAXXIFY Normalized: daxxify |
Drug | REVANCE THERAPEUTICS, INC. | $24.16 | 1 | 2025 |
Source payment records
|
|||||
| PAXLOVID Normalized: paxlovid |
Drug | PFIZER INC. | $22.45 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $18.69 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $18.69 | 1 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $17.13 | 1 | 2025 |
Source payment records
|
|||||
| LifeVest Normalized: lifevest |
Device | ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | $14.59 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 872 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 16 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
140 | 20 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
22 | suppressed by CMS |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | NUEDEXTA open payments reported associated product |
CMS Open Payments — General Payments 393 supporting records · 285 recipient NPIs · example record 1227268901 |
Nuedexta · 2024 Exact normalized brand match · 1 Part D row |
23 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
872 | 74 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 1050 | 198 |
| Eliquis | Apixaban | 872 | 74 |
| Gabapentin | Gabapentin | 659 | 141 |
| Amlodipine Besylate | Amlodipine Besylate | 644 | 139 |
| Trazodone Hcl | Trazodone Hcl | 501 | 110 |
| Gemtesa | Vibegron | 479 | 29 |
| Furosemide | Furosemide | 447 | 86 |
| Lisinopril | Lisinopril | 411 | 91 |
| Levothyroxine Sodium | Levothyroxine Sodium | 368 | 80 |
| Metoprolol Tartrate | Metoprolol Tartrate | 343 | 67 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 324 | 26 |
| Losartan Potassium | Losartan Potassium | 302 | 75 |
| Potassium Chloride | Potassium Chloride | 291 | 55 |
| Carvedilol | Carvedilol | 287 | 62 |
| Metformin Hcl | Metformin Hcl | 269 | 66 |
| Tamsulosin Hcl | Tamsulosin Hcl | 266 | 60 |
| Sertraline Hcl | Sertraline Hcl | 265 | 60 |
| Divalproex Sodium | Divalproex Sodium | 248 | 47 |
| Levetiracetam | Levetiracetam | 241 | 32 |
| Tramadol Hcl | Tramadol Hcl | 219 | 33 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 217 | 19 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 207 | 28 |
| Clopidogrel | Clopidogrel Bisulfate | 203 | 44 |
| Pantoprazole Sodium | Pantoprazole Sodium | 199 | 59 |
| Hydralazine Hcl | Hydralazine Hcl | 173 | 28 |
| Azithromycin | Azithromycin | 170 | 89 |
| Donepezil Hcl | Donepezil Hcl | 160 | 30 |
| Oxycodone Hcl | Oxycodone Hcl | 160 | 27 |
| Lorazepam | Lorazepam | 157 | 25 |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 153 | 61 |
| Lactulose | Lactulose | 153 | 21 |
| Baclofen | Baclofen | 150 | 33 |
| Duloxetine Hcl | Duloxetine Hcl | 147 | 32 |
| Ondansetron Hcl | Ondansetron Hcl | 146 | 60 |
| Xarelto | Rivaroxaban | 144 | 14 |
| Januvia | Sitagliptin Phosphate | 142 | 15 |
| Jardiance | Empagliflozin | 140 | 20 |
| Metoprolol Succinate | Metoprolol Succinate | 139 | 41 |
| Quetiapine Fumarate | Quetiapine Fumarate | 137 | 31 |
| Methylprednisolone | Methylprednisolone | 134 | 76 |
| Latanoprost | Latanoprost | 133 | 22 |
| Mirtazapine | Mirtazapine | 131 | 33 |
| Pregabalin | Pregabalin | 129 | 18 |
| Spironolactone | Spironolactone | 123 | 25 |
| Omeprazole | Omeprazole | 117 | 44 |
| Doxycycline Hyclate | Doxycycline Hyclate | 113 | 56 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 113 | 40 |
| Tizanidine Hcl | Tizanidine Hcl | 102 | 28 |
| Fluticasone Propionate | Fluticasone Propionate | 101 | 30 |
| Glipizide | Glipizide | 100 | 23 |
| Buspirone Hcl | Buspirone Hcl | 99 | 21 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 97 | 25 |
| Memantine Hcl | Memantine Hcl | 97 | 16 |
| Finasteride | Finasteride | 94 | 19 |
| Hydrochlorothiazide | Hydrochlorothiazide | 93 | 28 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 87 | 37 |
| Ropinirole Hcl | Ropinirole Hcl | 87 | 13 |
| Montelukast Sodium | Montelukast Sodium | 84 | 28 |
| Brimonidine Tartrate | Brimonidine Tartrate | 81 | 12 |
| Alprazolam | Alprazolam | 78 | 15 |
| Diclofenac Sodium | Diclofenac Sodium | 76 | 36 |
| Entresto | Sacubitril/Valsartan | 75 | 11 |
| Meloxicam | Meloxicam | 73 | 23 |
| Farxiga | Dapagliflozin Propanediol | 72 | 14 |
| Fiasp Flextouch | Insulin Aspart (Niacinamide) | 72 | 16 |
| Citalopram Hbr | Citalopram Hydrobromide | 70 | 21 |
| Famotidine | Famotidine | 70 | 24 |
| Allopurinol | Allopurinol | 68 | 17 |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 68 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 67 | 23 |
| Pravastatin Sodium | Pravastatin Sodium | 66 | 16 |
| Sumatriptan Succinate | Sumatriptan Succinate | 64 | 11 |
| Nystatin | Nystatin | 62 | 25 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 62 | 13 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 60 | 34 |
| Paroxetine Hcl | Paroxetine Hcl | 59 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 59 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 58 | 11 |
| Lacosamide | Lacosamide | 57 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 56 | 14 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 55 | suppressed |
| Olanzapine | Olanzapine | 54 | suppressed |
| Fiasp | Insulin Aspart (Niacinamide) | 53 | 13 |
| Diltiazem Hcl | Diltiazem Hcl | 52 | suppressed |
| Levofloxacin | Levofloxacin | 52 | 26 |
| Prednisone | Prednisone | 52 | 16 |
| Escitalopram Oxalate | Escitalopram Oxalate | 50 | 17 |
| Alendronate Sodium | Alendronate Sodium | 49 | 18 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 48 | 29 |
| Atenolol | Atenolol | 46 | suppressed |
| Levemir Flexpen | Insulin Detemir | 46 | 12 |
| Topiramate | Topiramate | 46 | 11 |
| Torsemide | Torsemide | 46 | suppressed |
| Dorzolamide-Timolol | Dorzolamide Hcl/Timolol Maleat | 45 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 45 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 44 | suppressed |
| Guanfacine Hcl | Guanfacine Hcl | 44 | suppressed |
| Nifedipine Er | Nifedipine | 43 | suppressed |
| Simvastatin | Simvastatin | 43 | 13 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 43 | 28 |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 42 | 12 |
| Oxcarbazepine | Oxcarbazepine | 42 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 41 | suppressed |
| Lamotrigine | Lamotrigine | 41 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 41 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 39 | 15 |
| Valproic Acid | Valproic Acid (As Sodium Salt) | 39 | suppressed |
| Cephalexin | Cephalexin | 38 | 24 |
| Midodrine Hcl | Midodrine Hcl | 38 | suppressed |
| Ozempic | Semaglutide | 37 | 16 |
| Insulin Glargine-Yfgn | Insulin Glargine-Yfgn | 36 | 14 |
| Methocarbamol | Methocarbamol | 36 | 15 |
| Symbicort | Budesonide/Formoterol Fumarate | 36 | 11 |
| Timolol Maleate | Timolol Maleate | 36 | suppressed |
| Novolog Flexpen | Insulin Aspart | 35 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 35 | suppressed |
| Fluconazole | Fluconazole | 34 | 15 |
| Warfarin Sodium | Warfarin Sodium | 34 | suppressed |
| Erythromycin | Erythromycin Base | 33 | suppressed |
| Fentanyl | Fentanyl | 33 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 33 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 33 | 13 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 32 | 13 |
| Estradiol | Estradiol | 32 | suppressed |
| Ibuprofen | Ibuprofen | 32 | 12 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 31 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 30 | suppressed |
| Ezetimibe | Ezetimibe | 30 | suppressed |
| Metolazone | Metolazone | 30 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 29 | suppressed |
| Humulin R | Insulin Regular, Human | 29 | suppressed |
| Nivestym | Filgrastim-Aafi | 29 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 29 | suppressed |
| Xifaxan | Rifaximin | 29 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 28 | suppressed |
| Ceftriaxone | Ceftriaxone Sodium | 28 | 20 |
| Gentamicin Sulfate | Gentamicin Sulfate | 28 | 15 |
| Methenamine Hippurate | Methenamine Hippurate | 28 | suppressed |
| Sucralfate | Sucralfate | 28 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 27 | 16 |
| Calcitriol | Calcitriol | 27 | suppressed |
| Moxifloxacin | Moxifloxacin Hcl | 27 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 26 | suppressed |
| Linzess | Linaclotide | 26 | suppressed |
| Methadone Hcl | Methadone Hcl | 26 | suppressed |
| Primidone | Primidone | 26 | suppressed |
| Progesterone | Progesterone, Micronized | 26 | suppressed |
| Sodium Chloride | 0.9 % Sodium Chloride | 26 | 16 |
| Humalog Kwikpen U-100 | Insulin Lispro | 25 | 12 |
| Soaanz | Torsemide | 25 | suppressed |
| Verapamil Er | Verapamil Hcl | 25 | suppressed |
| Bumetanide | Bumetanide | 24 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 24 | 11 |
| Lovastatin | Lovastatin | 24 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 23 | 13 |
| Clonazepam | Clonazepam | 23 | suppressed |
| Naltrexone Hcl | Naltrexone Hcl | 23 | suppressed |
| Nuedexta | Dextromethorphan Hbr/Quinidine | 23 | suppressed |
| Roflumilast | Roflumilast | 23 | suppressed |
| Dorzolamide Hcl | Dorzolamide Hcl | 22 | suppressed |
| Trulicity | Dulaglutide | 22 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 21 | suppressed |
| Enoxaparin Sodium | Enoxaparin Sodium | 21 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 21 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 21 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 20 | suppressed |
| Ondansetron Odt | Ondansetron | 20 | 11 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 20 | suppressed |
| Mupirocin | Mupirocin | 19 | suppressed |
| Nitroglycerin | Nitroglycerin | 19 | 14 |
| Santyl | Collagenase Clostridium Hist. | 19 | suppressed |
| Ssd | Silver Sulfadiazine | 19 | suppressed |
| Anastrozole | Anastrozole | 18 | suppressed |
| Atropine Sulfate | Atropine Sulfate | 18 | suppressed |
| Celecoxib | Celecoxib | 18 | suppressed |
| Ertapenem | Ertapenem Sodium | 18 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 18 | suppressed |
| Nyamyc | Nystatin | 18 | 12 |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 18 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 18 | suppressed |
| Amoxicillin | Amoxicillin | 17 | suppressed |
| Bethanechol Chloride | Bethanechol Chloride | 17 | suppressed |
| Colesevelam Hcl | Colesevelam Hcl | 17 | suppressed |
| Digoxin | Digoxin | 17 | suppressed |
| Ketorolac Tromethamine | Ketorolac Tromethamine | 17 | suppressed |
| Levemir | Insulin Detemir | 17 | suppressed |
| Lidocaine Hcl | Lidocaine Hcl/Pf | 17 | 14 |
| Terazosin Hcl | Terazosin Hcl | 17 | suppressed |
| Buprenorphine-Naloxone | Buprenorphine Hcl/Naloxone Hcl | 16 | suppressed |
| Ketoconazole | Ketoconazole | 16 | suppressed |
| Mounjaro | Tirzepatide | 16 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 16 | suppressed |
| Solu-Medrol | Methylprednisolone Sod Succ/Pf | 16 | 14 |
| Budesonide | Budesonide | 15 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 15 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 15 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 15 | suppressed |
| Biktarvy | Bictegrav/Emtricit/Tenofov Ala | 14 | suppressed |
| Brilinta | Ticagrelor | 14 | suppressed |
| Cilostazol | Cilostazol | 14 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 14 | suppressed |
| Glimepiride | Glimepiride | 14 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 14 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 14 | suppressed |
| Acyclovir | Acyclovir | 13 | suppressed |
| Bupropion Xl | Bupropion Hcl | 13 | suppressed |
| Calcium Acetate | Calcium Acetate | 13 | suppressed |
| Carbamazepine | Carbamazepine | 13 | suppressed |
| Myrbetriq | Mirabegron | 13 | suppressed |
| Prednisolone Acetate | Prednisolone Acetate | 13 | suppressed |
| Scopolamine | Scopolamine | 13 | suppressed |
| Atrovent Hfa | Ipratropium Bromide | 12 | suppressed |
| Glipizide Er | Glipizide | 12 | suppressed |
| Guanfacine Hcl Er | Guanfacine Hcl | 12 | suppressed |
| Gvoke Hypopen 1-Pack | Glucagon | 12 | suppressed |
| Paliperidone Er | Paliperidone | 12 | suppressed |
| Piperacillin-Tazobactam | Piperacillin Sodium/Tazobactam | 12 | suppressed |
| Prazosin Hcl | Prazosin Hcl | 12 | suppressed |
| Rivastigmine | Rivastigmine Tartrate | 12 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 12 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 12 | suppressed |
| Ammonium Lactate | Ammonium Lactate | 11 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 11 | suppressed |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 11 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $224.59 · 11 records | Bayer Healthcare Pharmaceuticals Inc. | DAXXIFY, ELIQUIS, Kerendia, LifeVest, MOUNJARO, NURTEC ODT, PAXLOVID, REXULTI, ZEPBOUND | 5 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Lilly USA, LLC?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error